Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 7,525 articles

Articles by Daniel Marsh

Tesla Shares Drop Amid Oil Spike, Mixed European Data
Markets

Tesla Shares Drop Amid Oil Spike, Mixed European Data

Tesla shares declined 2.6% to $391.92 Monday, pressured by rising oil prices and uneven European demand signals. The automaker raised the dual-motor Cybertruck price to $69,990.

TSLA USO XLE
Tesla Stock Dips Amid Oil Surge, Mixed European Data; Cybertruck Price Hike
Markets

Tesla Stock Dips Amid Oil Surge, Mixed European Data; Cybertruck Price Hike

Tesla shares declined in Monday trading as geopolitical tensions lifted oil prices and European demand signals were uneven. The automaker also raised the price of its dual-motor Cybertruck.

TSLA USO
BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference
Markets

BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference

BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO and targets a late-2027 regulatory submission.

BCRX
BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference
Analysis

BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference

BioCryst Pharmaceuticals shares fell nearly 3% in premarket trading following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO.

BCRX
BioCryst Shares Slip on New Hereditary Angioedema Drug Data
Analysis

BioCryst Shares Slip on New Hereditary Angioedema Drug Data

BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company reaffirmed its 2026 revenue outlook and plans a Phase 3 filing by late 2027.

BCRX XLV
Geopolitical Tensions Weigh on S&P 500 ETF as Oil Spikes
Markets

Geopolitical Tensions Weigh on S&P 500 ETF as Oil Spikes

The Vanguard S&P 500 ETF declined approximately 1% in premarket trading Monday following military action against Iran, sparking a surge in oil and safe-haven assets. U.S. stock index futures dropped over 1%.

VOO SPY USO GLD NVS NVDA XLE
Vanguard S&P 500 ETF Slides on Iran Strike Fears, Oil Surge
Markets

Vanguard S&P 500 ETF Slides on Iran Strike Fears, Oil Surge

Vanguard's S&P 500 ETF declined approximately 1% in Monday's premarket trading following military action against Iran, with oil prices jumping 8% and gold futures rising 3.4% as investors sought safety.

VOO SPY USO GLD NVS NVDA XLE XLF XLV XLK FXI MCHI
Geopolitical Tensions Weigh on VOO, S&P 500 Futures Slide
Markets

Geopolitical Tensions Weigh on VOO, S&P 500 Futures Slide

Vanguard's S&P 500 ETF declined approximately 1% before the bell Monday following military strikes on Iran, with oil surging 8% and gold futures rising 3.4% as investors sought safety.

VOO SPY NVDA USO GLD
AT&T Shares Dip Amid Risk-Off Sentiment, Investors Eye Executive Commentary
Markets

AT&T Shares Dip Amid Risk-Off Sentiment, Investors Eye Executive Commentary

AT&T shares edged lower in premarket activity Monday, tracking a broader market retreat fueled by geopolitical concerns and inflation jitters. Attention turns to executive commentary at upcoming telecom conferences.

T USO
AT&T Shares Dip Amid Broader Market Retreat, Focus Turns to Executive Commentary
Markets

AT&T Shares Dip Amid Broader Market Retreat, Focus Turns to Executive Commentary

AT&T shares declined 0.36% to $27.91 in premarket activity Monday as broader market futures fell over 1%. The telecom giant's executives are scheduled to speak at industry conferences this week, with investors seeking updates on subscriber trends and capital plans.

T USO
Netflix Exits Warner Bros. Discovery Talks Over Price, Paramount Deal in Focus
Markets

Netflix Exits Warner Bros. Discovery Talks Over Price, Paramount Deal in Focus

Netflix has withdrawn from acquisition discussions with Warner Bros. Discovery, with co-CEO Ted Sarandos stating a firm price ceiling of $27.75 per share. This development comes as Paramount Skydance's competing $31.00 all-cash offer undergoes regulatory review.

NFLX WBD
Apple Shares Dip Amid Geopolitical Tensions Ahead of Product Launch Week
Markets

Apple Shares Dip Amid Geopolitical Tensions Ahead of Product Launch Week

Apple shares declined over 1% before the bell following a 3.2% drop Friday, pressured by broader market risk-off sentiment driven by Middle East tensions. The tech giant faces a pivotal week with product launches and a legal deadline.

AAPL USO XLK